Nivolumab + platinum/fluoropyrimidine chemotherapy (ESCC)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-NIVOLUMAB` `DRUG-CISPLATIN` `DRUG-5-FLUOROURACIL`

ID	`REG-NIVO-CHEMO-ESCC`
Type	Regimen
Status	reviewed 2026-05-07 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-ESOPHAGEAL-2024` `SRC-NCCN-ESOPHAGEAL-2025`

Notes

Thin regimen alias added to resolve existing esophageal ESCC indication references. Detailed dose/schedule curation should reconcile with the canonical esophageal 1L regimen set.

Used By

Indication

IND-ESOPH-METASTATIC-1L-NIVO-CHEMO-SCC - IND-ESOPH-METASTATIC-1L-NIVO-CHEMO-SCC

Regimen

REG-IPI-NIVO-ESOPH-SCC - Nivolumab + ipilimumab (ESCC, 1L metastatic; CheckMate-648)